iCAD

iCAD, Inc. is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iCAD implements strategic changes to drive profitability and growth

iCAD is strategically focusing on cost reduction, revenue diversification, and transitioning to a subscription model to drive profitability by 2024. Leveraging partnerships with Google and other organizations, the company aims to expand its market reach and enhance operational efficiency. Despite facing competition and market challenges, iCAD remains optimistic about its growth prospects.

iCAD reports Q1 revenue decline, eyes growth in AI healthcare

iCAD faced revenue decline in Q1 2023, with a focus on detection and therapy segments, while maintaining a strong gross profit margin.
The company's Xoft technology and partnership with Google Health present promising growth opportunities in the AI healthcare space.
Challenges include lower-than-expected Xoft business revenue, competition in AI software, and delays in partnership agreements.

iCAD reports Q2 revenue decline, eyes growth through strategic partnerships

iCAD's Q2 2023 Earnings Call showcased a revenue decline but highlighted progress in the detection segment and strategic partnerships. The company aims for recurring revenue through subscription deals and is focused on cost reductions and stability. Opportunities lie in expanding partnerships and securing growth with healthcare facilities globally.

iCAD reports improved operational metrics and strategic partnerships in Q3 '23

iCAD's Q3 '23 earnings call highlighted operational improvements, strategic partnerships, and a focus on growth initiatives. Despite a revenue decline and operating loss, the company has made progress in reducing EBITDA loss and cash burn. iCAD's financial position remains stable with sufficient resources for planned operations.

iCAD reports improved financials and strategic growth initiatives for 2024

iCAD's financial performance showed improvements in revenue, EBITDA loss, and operational efficiency, driven by strategic initiatives.
The company's focus on AI solutions, geographic expansion, and recurring revenue model positions it for future growth.
While facing challenges in market adoption and OpEx increases, iCAD has opportunities to capitalize on market growth and new product developments.

iCAD reports revenue growth and strategic expansion in Q1 2024

iCAD's Q1 2024 performance reflects positive momentum with revenue growth, improved profitability metrics, and strategic advancements
The company's focus on innovation, market expansion, and cost control positions them well for future growth and market leadership
While challenges like revenue seasonality and competitive pressures exist, iCAD's strengths in product development and global expansion offer opportunities for sustained growth
Overall, iCAD's Q1 2024 earnings call underscores a promising outlook with a strong foundation for continued success in the medical technology sector

iCAD reports 4% revenue growth, FDA clearance boosts cancer detection

iCAD's Q3 performance reflects growth in revenue and strategic partnerships, underpinned by AI technology.
While facing challenges in service revenue and net loss, the company's global expansion and product advancements signal resilience.
Opportunities lie in market expansion, innovation in breast cancer detection, and transitioning to a recurring revenue model.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

C3.ai

Schrodinger 

Wall Street has correctly recognized that artificial intelligence (AI) is a game-changer. It enables individuals to use computers more easily than ever before to find the best answers to complex questions.

The Hot List: 3 AI Stocks Worth Buying on Weakness

NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, Feb 28 – March 3, 2024. The Company also announced it will highlight a new release for its AI-powered ProFound Detection solution while showcasing its full Breast Health Suite in booth X1 AI-35.

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Dr. Hricak offers extensive experience in radiology, real-world application of AI-enabled imaging solutions, research, and global healthcare perspectives Dr. Hricak offers extensive experience in radiology, real-world application of AI-enabled imaging solutions, research, and global healthcare perspectives

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024.

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Blink Charging

Bionano Genomics

While it's never easy to identify multibagger stocks, this may be one of the best times in decades to “swing for the fences” by buying undervalued growth names that are well-positioned to at least triple over the next few years. Amid excessive worries about interest rates, the Street has pushed down many unprofitable, high-potential companies' stocks to absurdly low levels.

Wealth Accumulation: 3 Stocks with Multibagger Potential

NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence (AI) powered solutions from iCAD's ProFound Breast Health Suite are the first applications to be offered in GE HealthCare's new MyBreastAI Suite* offering.

iCAD's AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman's one to two-year risk for breast cancer iCAD unveils new solution that assesses calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease, the leading cause of death for women in the U.S. Dr. Emily Conant, Perelman School of Medicine, University of Pennsylvania, to present how iCAD's 4 th generation Breast AI is harnessing innovations to improve patient outcomes NASHUA, N.H., Nov. 27, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, will present new studies validating its artificial intelligence (AI) powered ProFound Breast Health Suite for uncovering hidden heart or vascular disease and predicting a woman's risk for developing breast cancer in the next one- or two-years.

iCAD's ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

SoundHound AI Inc

Wallbox NV

Penny stocks are usually small-cap stocks, and small-cap stocks typically tend to perform the best during the early stages of the business cycle when the economy is recovering and growing fairly rapidly. Multi-billionaire investor Ken Fisher has indicated that we are in the early stages of the business cycle, and I agree with him.

Discover Future Growth Stocks: 3 Penny Stocks Poised for Massive Returns

NASHUA, N.H., Nov. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, President and Chief Executive Officer and Eric Lonnqvist, Chief Financial Officer, will participate at the 14th Annual Craig-Hallum Alpha Select Conference on Thursday, November 16th. The conference will be held at the Sheraton New York Times Square in New York City.

iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference

Vodacom Group Limited (OTCPK:VODAF) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Leonor Faber - Assistant to Chief Executive Officer Dana Brown - President & Chief Executive Officer Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallum Capital Operator Good day, everyone and welcome to the iCAD, Inc. Third Quarter 2023 Earnings Call. At this time, all participants have been placed in a listen-only mode and we will open the floor for your questions and comments after the presentation.

iCAD, Inc. (ICAD) Q3 2023 Earnings Call Transcript

NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2023.

iCAD Reports Financial Results for Third Quarter Ended September 30, 2023

NASHUA, N.H., Oct. 30, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that it will release financial results for the third quarter ended September 30, 2023, after the market close, and host a conference call at 4:30 PM Eastern Time on Monday, November 13, 2023.

iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023

BigBear.ai Holdings

Himax Tech

Lantern Pharma

Remark Hlds

Veritone

Dive into the dynamic realm of undervalued AI penny stocks, offering robust long-term upside potential. By 2030, artificial intelligence (AI) is set to fuel the global economy with a staggering $15.7 trillion injection.

The 7 Most Undervalued AI Penny Stocks to Buy: October 2023

Xoft's eBx System can now be offered to more clinics and cancer patients world-wide through Elekta's extensive sales channels Xoft's eBx System can now be offered to more clinics and cancer patients world-wide through Elekta's extensive sales channels

iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta

ASML Hld

Alphabet

ServiceNow

Super Micro Computer

The transformative power of artificial intelligence ( AI ) — with regards to drug makers and banks to oil companies to every firm that carries out intensive sales activities — is widely known. Yet in spite of all of these points, it appears that the Street — which has been much more focused on a one percentage point change in bond rates lately than the revolutionary power of AI — is giving very few AI stocks the credit they deserve.

7 Trailblazing AI Stocks to Buy on Any Weakness

CyberArk Software

EMCOR Group

In this era that features extremely rapid advances in technology and an energy revolution, there are many up-and-coming sectors and a multitude of great up-and-coming stocks to buy. Investors can choose from companies benefiting from the renewable energy boom, the growing demand for electric vehicles, the autonomous-driving trend, the Internet of Things revolution, the explosion of the cloud and data centers, the tremendous demand for more effective internet security, and of course, the artificial intelligence revolution.

3 Up-and-Coming Stocks to Put on Your Must-Buy List

NASHUA, N.H., Aug. 16, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health Canada has issued a device license for ProFound Risk version 2.0, the latest version of iCAD's personalized 1-2 year breast cancer risk assessment solution.

Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment

iCAD, Inc. (NASDAQ:ICAD ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Jessica Burns – Head-Global Communications Dana Brown – President and Chief Executive Officer Eric Lonnqvist – Chief Financial Officer Conference Call Participants Per Ostlund – Craig-Hallum Capital Sam Eiber – BTIG Yale Jen – Laidlaw & Company Frank Takkinen – Lake Street Capital Operator Greetings. Welcome to the iCAD Inc. Second Quarter 2023 Earnings Call.

iCAD, Inc. (ICAD) Q2 2023 Earnings Call Transcript

NASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2023.

iCAD Reports Financial Results for Second Quarter Ended June 30, 2023

Archer Aviation

Evolv Technologies Holdings

IonQ

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.

5 AI Stocks That Could Turn $50,000 Into $1 Million

NASHUA, N.H., July 31, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will release financial results for the second quarter of 2023 and host a conference call at 4:30 PM ET on Monday, August 14, 2023.

iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023

Baidu

Datadog

HubSpot

Symbotic Inc

XPeng

Remember The Game of Thrones? If I had to describe investing in stocks in only four words, it would be “The Game of Trends.

If You Can Only Buy One Tech Stock, It Better Be One of These 7 Names

Agreement positions iCAD as Radiology Partners' breast AI provider, expanding potential for iCAD's technology to reach millions of women in the U.S. Agreement positions iCAD as Radiology Partners' breast AI provider, expanding potential for iCAD's technology to reach millions of women in the U.S.

iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation's Largest Radiology Practice

Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD's Breast AI Suite helps her detect the breast cancers radiologists fear most Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD's Breast AI Suite helps her detect the breast cancers radiologists fear most

iCAD's “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic

Company's ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities Company's ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities

News for iCAD Stock (ICAD)